Eli Lilly is a global pharmaceutical company dedicated to discovering, developing, manufacturing, and marketing innovative medicines that address some of the world's most challenging health issues. The company focuses on areas such as diabetes, oncology, immunology, and neurodegenerative diseases, providing a wide range of treatments designed to improve patient outcomes and quality of life. Eli Lilly is committed to scientific advancement and works collaboratively with healthcare professionals and researchers to bring new therapies and solutions to market, ensuring access to life-saving medications for patients around the globe. Read More
As the first quarter of 2026 unfolds, the euphoric bull market that defined the mid-2020s has hit a formidable wall of uncertainty. A potent cocktail of geopolitical instability in the Middle East and South America, coupled with a domestic crisis of confidence in central bank leadership, has sent major indices
In a day marked by heightened global tensions and a sharp spike in energy prices, the U.S. equity markets witnessed a decisive "Great Rotation" as investors abandoned high-growth technology names in favor of battle-tested stalwarts. On Friday, March 13, 2026, JPMorgan Chase & Co. (NYSE: JPM) and Eli Lilly and
As of March 13, 2026, the healthcare landscape has witnessed one of the most significant pivots in the history of digital health. Hims & Hers Health, Inc. (NYSE: HIMS) has officially transitioned from a controversial provider of compounded GLP-1 medications to a cornerstone of the global pharmaceutical distribution network. The catalyst for this transformation was [...]
Date: March 12, 2026 Introduction Dianthus Therapeutics (NASDAQ: DNTH) has become the center of Wall Street’s attention today, with its share price surging 19.4% in early trading following a pivotal update from its Phase 3 CAPTIVATE trial. The company, which specializes in "next-generation" complement inhibitors, announced that its lead candidate, claseprubart (DNTH103), met early responder [...]
As of March 12, 2026, the healthcare landscape has been fundamentally reshaped by the intersection of digital platforms and the "obesity gold rush." At the center of this transformation is Hims & Hers Health (NYSE: HIMS), a company that has navigated a volatile journey from a telehealth disruptor to a central pillar of the modern [...]
Hims & Hers shares extend gains as Eli Lilly warns impurity it discovered in compounded versions of its weight-loss drug has health implications. Here’s why HIMS stock isn’t worth owning here.
The weight-loss drug market witnessed a tectonic shift this week as Hims & Hers Health, Inc. (NYSE: HIMS) announced a comprehensive legal settlement and strategic partnership with pharmaceutical giant Novo Nordisk (NYSE: NVO). The deal, which effectively ends a high-stakes patent dispute, has propelled HIMS shares to record highs, closing the
As of March 11, 2026, the Dow Jones Industrial Average is grappling with a heavyweight problem. UnitedHealth Group (NYSE: UNH), long the gold standard of the managed care sector and a primary engine of the index’s growth over the last decade, has transformed into its most significant anchor. With
Andel launches a PBM-free employer platform offering Eli Lilly and Company's (NYSE: LLY) Zepbound KwikPen at lower cash prices. CEO Jay Bregman tells Benzinga how the model works and why PBMs can't copy it.
Hunterbrook had shorted Hims in 2024, warning its GLP-1 strategy relied on a regulatory loophole during drug shortages and could face legal risks tied to patents.
On a day marked by deepening global uncertainty and a sharp spike in energy costs, the healthcare sector emerged as the primary beneficiary of a massive "risk-off" migration by institutional investors. As of the market close on March 10, 2026, the Healthcare Select Sector SPDR Fund (NYSEARCA:XLV) gained 1%
